《大行》交銀國際對醫藥股投資評級及目標價(表)
交銀國際發表研究報告, 對醫藥股投資評級及目標價表列如下:
股份 | 投資評級 | 目標價
阿斯利康(AZN.US) | 買入 | 93.3美元
百濟神州(06160.HK) | 買入 | 208.8港元
翰森製藥(03692.HK) | 買入 | 33港元
信達生物(01801.HK) | 買入 | 84港元
中國生物製藥(01177.HK) | 買入 | 5.9港元
科倫博泰生物-B(06990.HK) | 買入 | 400港元
傳奇生物(LEGN.US) | 買入 | 65美元
藥明合聯(02268.HK) | 買入 | 51港元
和黃醫藥(00013.HK) | 買入 | 44港元
先聲藥業(02096.HK) | 買入 | 14.3港元
通化東寶(600867.SH) | 買入 | 14元人民幣
雲頂新耀(01952.HK) | 買入 | 65港元
康諾亞-B(02162.HK) | 買入 | 57港元
錦欣生殖(01951.HK) | 買入 | 3.75港元
固生堂(02273.HK) | 買入 | 42港元
恆瑞醫藥(600276.SH) | 中性 | 51元人民幣
石藥集團(01093.HK) | 中性 | 7.2港元
科倫藥業(002422.SZ) | 中性 | 40.2元人民幣
百時美施貴寶(BMY.US) | 沽售 | 33.1美元
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.